PAOLA-1 Phase 3 trial

January 12, 2021January 12, 2021

Lynparza Approved in Japan to Treat Certain Advanced Ovarian Cancers

News

Lynparza (olaparib) has been approved in Japan as a maintenance treatment for women with advanced ovarian cancer who responded to a first-line chemotherapy regimen containing bevacizumab, AstraZeneca and Merck announced in a ... Read more

November 10, 2020January 12, 2021

Lynparza Combo Approved in EU as First-line Maintenance for Advanced Ovarian Cancer

News

The European Commission has approved Lynparza (olaparib), in combination with bevacizumab, as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who ... Read more

September 24, 2020September 24, 2020

Lynparza Combo Recommended by EU Committee as First-line Maintenance for Advanced Ovarian Cancer

News

Lynparza (olaparib), in combination with bevacizumab, has been recommended for approval in the European Union (EU) as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who ... Read more

February 19, 2020February 19, 2020

Myriad Asks FDA to Approve myChoice CDx to Find Potential Lynparza Candidates

News

Myriad Genetics submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its myChoice CDx test to identify ovarian cancer patients likely to benefit from first-line ... Read more

December 5, 2019December 9, 2019

China OKs Lynparza as Maintenance Therapy for Advanced Ovarian Cancers with BRCA Mutations

News

Oral Lynparza (olaparib) has been approved in China as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer who responded to initial platinum-based chemotherapy, AstraZeneca and Merck (known as MSD ... Read more

October 30, 2019October 30, 2019

Lynparza-Avastin First-Line Maintenance Therapy Delays Cancer Progression in Advanced OC, Phase 3 Study Shows

News

Adding Lynparza (olaparib) to Avastin (bevacizumab) as a first-line maintenance treatment significantly delayed disease progression in women with advanced ovarian cancer — regardless of BRCA mutation status — interim data from a Phase ... Read more

July 8, 2019

Lynparza Approved in Japan as First-Line Maintenance Therapy for Advanced OC

News

Lynparza (olaparib) has been approved in Japan as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer that is responding, partially or completely, to their initial chemotherapy, AstraZeneca and Merck (known ... Read more

May 8, 2019

Lynparza Recommended for Approval in Europe for BRCA-mutated Advanced OC

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended that Lynparza (olaparib) be approved as a first-line maintenance therapy for women with ... Read more